Suboptimal immune response among adults on first-line antiretroviral therapy within the IeDEA East Africa cohort Authors: Nakanjako D, Kiragga A, Yiannoutsos.

Slides:

Advertisements

Similar presentations

Antiretroviral Therapy: An HIV Prevention Strategy? Wafaa El-Sadr, MD, MPH Columbia University Harlem Hospital New York.

Advertisements

High rates of survival, virologic suppression and immune reconstitution among patients receiving second-line ART in the Indian national programme B.B.

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Improved retention in HIV care following SMS reminders in Mozambique Authors: D. Joseph Davey*,

Tuberculosis incidence and risk factors among adult patients receiving HAART in Senegal: a 7-year cohort study Assane DIOUF et al. IRD/UMR 145 CRCF, CHNU.

Antiretroviral therapy eligibility at enrollment and time to treatment initiation in Ethiopia Chloe A. Teasdale 1, Chunhui Wang 1, Sileshi Lulseged 1,

Retention across the continuum of care in a cohort of HIV infected children in rural India G. Alvarez-Uria RDT Hospital, Department of Infectious Diseases,

Estimated Incidence of AIDS and Deaths of Adults with AIDS, January 1985-June 2000, United States The upper curve represents estimated AIDS incidence.

Effects of patient tracing on estimates of lost to follow-up, mortality and retention in antiretroviral therapy programs in low-middle income countries:

Is monitoring for CD4 counts still needed for the management of patients with long- term HIV RNA suppression? Andrew Hill, Liverpool University, UK.

1 Is Managed Care Superior to Traditional Fee-For-Service among HIV-Infected Beneficiaries of Medicaid? David Zingmond, MD, PhD UCLA Division of General.

1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Challenges of service integration: the TB model Linda-Gail Bekker The Desmond Tutu HIV Centre, Faculty of Health Sciences, University of Cape Town, South.

Using HIV Surveillance to Achieve High Impact Prevention Irene Hall, PhD, FACE AIDS 2012 High-Impact Prevention: Reducing the HIV Epidemic in the United.

Catherine Kober Margaret Johnson Martin Fisher Caroline Sabin On behalf of UK-CHIC BHIVA/BASHH Manchester 2010 Non-uptake of HAART among patients with.

Office of Overseas Programming & Training Support (OPATS) Treatment Adherence HIV Care, Support, and Treatment.

EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.

ICAP Track 1.0 Year 6: Reaching Targets Focus on Quality Continued Innovations David Hoos, MD, MPH Dar es Salaam August 4, 2009.

Is Highly Active Antiretroviral Therapy (HAART) in pregnancy protective against maternal mortality? Results from a large DREAM cohort in Malawi and Mozambique.

The Positive Predictive Value of World Health Organization (WHO) Immunologic Criteria for Treatment Failure in a Public Health Antiretroviral Delivery.

Challenges to replacing CD4 testing with viroloigical monitoring Andrew Hill, Pharmacology Research Laboratories, University of Liverpool, UK World AIDS.

TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)

Immune Discordance on Highly Active Antiretroviral Therapy Can Still be Regarded as a Therapeutic Success Nur F. Önen MD, MRCP 1, Rachel Presti MD PhD.

Press Briefing: Office of the Vice Chancellor MUK 6 th September 2010 The Infectious Diseases Institute Care and Research Initiatives Dr Alex G Coutinho.

Factors Associated with Survival in HIV-Infected African Patients on Antiretroviral Therapy: The Impact of a Sampling-Based Approach to Address Losses.

Community-based Adherence Clubs improve outcomes for stable ART patients: Outcomes from Cape Town, South Africa Anna Grimsrud 1, Maia Lesosky 1,2, Cathy.

History of Opportunistic Complications: Should This Remain An Exclusionary Criterion? Kathleen E. Squires, M.D. Associate Professor of Medicine Keck School.

ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.

HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The United Kingdom provides excellent access and quality of.

Good Three-year Outcomes of Antiretroviral Therapy at Multiple NGO- assisted facilities in Four Provinces in South Africa Geoffrey Fatti, Ashraf Grimwood.

Retention in Care among HIV-infected Patients Receiving Antiretroviral Therapy in Africa: Estimation via a Sampling-based Approach Elvin Geng 1, David.

1 The impact of ongoing illicit drug use on virologic suppression in HIV-infected injection drug users receiving HAART Authors: Harout Tossonian, Jesse.

Declines in adult HIV mortality in Botswana, : evidence for an impact of antiretroviral therapy programs Rand Stoneburner, Dominic Montagu, Cyril.

MISSING DATA IN THE INFECTIOUS DISEASES INSTITUTE CLINIC DATABASE Agnes N Kiragga East Africa IeDEA investigators’ meeting 4-5 th May 2010 East African.

Outcomes of Antiretroviral Treatment Programs in Rural Lesotho: Health Centers and Hospitals Compared Niklaus Labhardt, Motlalepula Sello, Mamokone A.

WORLD AIDS DAY Zero new HIV infections Zero discrimination Zero AIDS-related deaths.

Mövenpick Royal Palm Hotel Dar es Salaam, Tanzania August 4-6, 2009 The 7th Annual Track 1.0 ART Program Meeting.

MINNESOTA’S HIV TREATMENT CASCADE April, Introduction.

Outcomes in ART treatment programmes with and without access to routine viral load monitoring Olivia Keiser on behalf of IeDEA Southern Africa

Retention in care and connection to care among HIV-infected patients receiving ART n Africa: Estimation via a sampling-based approach Elvin Geng 1, David.

1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.

Can early antiretroviral therapy fully restore health? Workshop on Pathogeneses and Management of Long-Term Complications of ART IAS Conference, Rome July.

Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Figure 2: Trends in currently prescribed antiretroviral therapy % prescribed HAART increased from 74% to 83% Trends in ART use, HIV viral load, and CD4.

1 Uses of Data from the WHO HIV Drug Resistance Strategy: 1. Monitoring of HIVDR emerging in treated groups in sentinel ART clinics HIV Drug Resistance.

Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.

CD4 trajectory among HIV positive patients receiving HAART in a large East African HIV care centre Agnes N. Kiragga 1, Beverly Musick 2 Ronald Bosch, Ann.

Improving Patients Retention in Antiretroviral Treatment Programs: The experience of ARV Programs in Côte d’Ivoire Eugène MESSOU, MD, PhD CePReF- Aconda.

Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Antiretroviral Therapy on Viral Load, CD4.

1 Predictors of Immunological Failure Among Adult Patients Receiving ART at an urban, HIV Clinic in Uganda Dr. Muhumuza Simon (M.D, MPH) Mulago-Mbarara.

Priscilla Tsondai, Lynne Wilkinson, Anna Grimsrud, Angelina Trivino,

Factors associated with loss to follow up in a primary healthcare clinic practicing test and treat Authors: Julius Kiwanuka1,2, Noah Kiwanuka3, Flavia.

Earlier treatment and lower mortality in infants Initiating ART at

Viral Suppression at the First Integrated Methadone and Antiretroviral Therapy Program for People who Inject Drugs in sub-Saharan Africa Dar es Salaam,

Title Factors associated with viral suppression among adolescents living with HIV in Cambodia “No conflicts of interest to declare”

coinciding with biphasic immune reconstitution

Nnambalirwa Maria1, Denise Evans2, Lynne McNamara3, Peter Nyasulu4,

First roll out of universal access to antiretroviral therapy under routine program conditions in rural Swaziland. Authors: Bernhard Kerschberger (1), Sikhathele.

HIV Care Continuum in Manhattan

1University of Maryland; 2Futures Group International; 3CDC; 4USAID

WHO HIV update July 2018 Global epidemic Global progress and cascade

Juan Gonzalez Perez AIDS Healthcare Foundation

Dr. Velephi Okello, Principal Investigator, MaxART Trial

Dorina Onoya1, Tembeka Sineke1, Alana Brennan1,2, Matt Fox1,2

Knowing your epidemic and knowing your response – maximising routinely collected data to measure and monitor HIV epidemics in sub-Saharan Africa Monitoring.

Volume 381, Issue 9875, Pages (April 2013)

When to START During an OI

Volume 375, Issue 9709, Pages (January 2010)

Conflicting of interest disclosure: None

Volume 373, Issue 9672, Pages (April 2009)

Keep control: Elite and post-treatment controllers

Presentation transcript:

Suboptimal immune response among adults on first-line antiretroviral therapy within the IeDEA East Africa cohort Authors: Nakanjako D, Kiragga A, Yiannoutsos C, Kambugu A, Easterbrook P, on behalf of IeDEA- EA Abstract # TUPDB0105 IAS 30th June-3 July 2013, Kuala Lumpar Malaysia

Definitions of suboptimal CD4 recovery i)magnitude criteria: CD4 increase <50 cells at 6 months, <100 cells at 12 months and <200 cells at 24 months ii)CD4 threshold criteria: absolute CD4 count <200 cells/UL at 6, 12 and 24 months iii) Population-specific criteria: Lowest quartile CD4 count increases in the HAART cohort Tuboi SH, JAIDS 2007, Lawn SD, BMC ID, 2007, Lawn SD, AIDS 2001

Statistical methods Used Kaplan Meier survival analysis to analyse time to normalization (CD4 > 500 cells) Considered competing risks of death and loss to follow-up

Overall 83,926 adults initiated antiretroviral therapy at 7 sites in East Africa 6 months (27%) In-care with a CD4 measurement 24 months (12%) In-care with a CD4 measurement CD4 recovery SuboptimalOptimalSuboptimalOptimal 5528 (25%)17501 (75%) 5183 (51%)5049 (49%) OI after suboptimal response 996 (18%)12498 (14%) 612 (12%)463 (9%) P<0.0001P=0.0001

Incidence of normalisation with competing risks of death and Loss to follow up Years from ART initiation Cumulative incidence of achieving CD4≥ 350 cells/UL Cumulative incidence of achieving CD4≥500 cells/UL 126.3%15.9% 241.5%22.0% 349.9%27.3% 454.7%33.2% 557.7%37.7% 659.8%40.8% 726.6%34.4% 861.9%45.2% 98.6%36.4% %49.8%

Policy issues Need to increase access to routine CD4 in routine HIV care & treatment programs Routine viral loads for poor CD4 responders to identify suboptimal responder population Increase adherence and retention in care to allow quality follow up Interventions to optimise immune recovery among suboptimal responders despite viral suppression

Acknowledgement